anti-Glicentin-related polypeptide (GRPP) Antibodies

The protein encoded by GRPP is actually a preproprotein that is cleaved into four distinct mature peptides.

list all antibodies Gene Name GeneID UniProt
GRPP 2641 P01275
GRPP 14526 P55095
GRPP    
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online
  • orders@antibodies-online.com

Top anti-Glicentin-related polypeptide Antibodies at antibodies-online.com

Showing 10 out of 12 products:

Catalog No. Reactivity Host Conjugate Application Images Quantity Supplier Delivery Price Details
Mouse Rabbit Un-conjugated IF (p), IHC (p)   100 μL Log in to see 3 to 7 Days
$317.90
Details
Human Rabbit Carboxyfluorescein (CFS) ELISA   100 μL Log in to see 16 Days
$1,166.00
Details
Human Rabbit Un-conjugated ELISA   200 μg Log in to see 11 to 16 Days
$1,005.71
Details
Human Rabbit Biotin ELISA   100 μL Log in to see 16 Days
$1,166.00
Details
Human Rabbit Un-conjugated IHC   100 μL Log in to see 13 to 15 Days
$688.60
Details
Human Rabbit Un-conjugated WB   200 μg Log in to see 13 to 15 Days
$688.60
Details
Human Rabbit FITC   100 μL Log in to see 13 to 15 Days
$688.60
Details
Human Rabbit Biotin   100 μL Log in to see 13 to 15 Days
$765.44
Details
Human Rabbit FAM   100 μL Log in to see 13 to 15 Days
$765.44
Details
Human Rabbit DyLight 647   100 μL Log in to see 13 to 15 Days
$840.81
Details

More Antibodies against Glicentin-related polypeptide Interaction Partners

Human Glicentin-related polypeptide (GRPP) interaction partners

  1. GPR119 is the oleoyl-lysophosphatidylinositol receptor that is required for GLP-1 secretion in enteroendocrine cells.

  2. RYGB increased circulating bile acids, ileal Takeda G protein-coupled receptor 5 (TGR5) and mTORC1 signaling activity, as well as GLP-1 production in both mice and human subjects. Inhibition of ileal mTORC1 signaling by rapamycin significantly attenuated the stimulation of bile acid secretion, TGR5 expression and GLP-1 synthesis induced by RYGB in lean and diet-induced obese mice.

  3. Glucagon role in the pathophysiology of type 2 diabetes.[review]

  4. This review summarizes the current knowledge regarding the role of GLP-1 in the protection against oxidative damage and the activation of the Nrf2 signaling pathway. [review]

  5. Study concludes that in healthy subjects, glucagon-like peptide-1 (GLP-1) increases cardiac output acutely due to a GLP-1-induced vasodilation in adipose tissue and skeletal muscle together with an increase in cardiac work.

  6. Chenodeoxycholic acid stimulates glucagon-like peptide-1 secretion in patients after Roux-en-Y gastric bypass.

  7. The results demonstrate that glucagon-like peptide-1 and insulin synergistically and additively activate vagal afferent neurons.

  8. DPP-4 activity and GLP-1total levels were higher in patients with microvascular complications associated with T2DM. Contrary to expectations, no negative correlation was seen between GLP-1 and DDP-4 levels. This result suggests the possible inefficacy of DDP-4 activity as a marker to predict in vivo degradation of endogenous GLP-1.

  9. Data suggest that cAMP acts as amplifier of insulin secretion triggered by Ca2+ elevation in beta-cells; both messengers are also positive modulators of glucagon release from alpha-cells, but in this case cAMP signaling may be the important regulator and Ca2+ signaling has a more permissive role. [REVIEW]

  10. This study provides evidence that, in HepG2 cells, GLP-1 may affect cholesterol homeostasis by regulating the expression of miR-758 and ABCA1.

  11. This study reports the transition dipole strengths and frequencies of the amyloid beta-sheet amide I mode for the aggregated proteins amyloid-beta1-40, calcitonin, alpha-synuclein, and glucagon.

  12. genetic association studies in population in China: Data confirm that an SNP in an intron of SLC47A1 (rs2289669) is associated with hypoglycemic response to metformin in patients with newly diagnosed type 2 diabetes; differential increases in basal GLP1 plasma levels are also related to this SNP. (SLC47A1 = solute carrier family 47 member 1; GLP1 = glucagon-like peptide-1)

  13. GLP-2 augmented BRIN BD11 beta-cell proliferation, but was less efficacious in 1.1B4 cells. These data highlight the involvement of GLP-2 receptor signalling in the adaptations to pancreatic islet cell stress.

  14. Everolimus down-regulates the systemic levels of gastrin and glucagon in patients with pancreatic neuroendocrine tumors.

  15. Glucagon-like peptide (GLP-2) stimulates cancer myofibroblast proliferation, migration and invasion; GLP-2 acts indirectly on epithelial cells partly via increased Insulin-like growth factor (IGF) expression in myofibroblasts.

  16. Describe model, in which the release of GIP/GLP-1 is stimulated by glucose in the proximal small intestine, and no differences in the secretion dynamics between healthy individuals and patients with T2D are identified after taking differences in glucose profiles into account.

  17. the solvent exposure of the two Phe sites along the glucagon sequence was determined, showing that 4F-Phe6 was fully solvent exposed and 4F-Phe22 was only partially exposed

  18. Data suggest that dose/intensity-response relationships exist between exercise intensity and total plasma PYY levels, though the effects on total plasma GLP1 levels and hunger perceptions seem unclear. (PYY = peptide YY ; GLP1 = glucagon-like peptide 1)

  19. GLP-2 could be considered an hormone causing positive energy balance, which, however has the role to mitigate the metabolic dysfunctions associated with hyper-adiposity. [review]

  20. Studies indicate that nutrient-induced glucagonlike peptide-1 (GLP-1) response was one of the best predictors of type 2 diabetes mellitus (T2DM) remission after Roux-en-Y-gastric-bypass (RYGB).

Mouse (Murine) Glicentin-related polypeptide (GRPP) interaction partners

  1. PPG-derived GLP-1/2 are probably key neuroendocrine signals for the control of energy balance and glucose homeostasis. The objective of this study was to determine whether activation of PPG neurons per se modulates glucose homeostasis and insulin sensitivity in vivo.

  2. Data suggest that Tas1r2 and Tas1r3 are involved in regulation of Glp1 secretion in enteroendocrine cells; 3DG (3-deoxyglucosone) attenuates high glucose-stimulated Glp1 secretion by antagonizing Tas1r2/Tas1r3 subunits and downstream cAMP signaling. (Tas1r2 = sweet taste receptor subunit Tas1r2; Tas1r3 = sweet taste receptor subunit Tas1r3; Glp1 = glucagon-like peptide-1)

  3. GPR119 is the oleoyl-lysophosphatidylinositol receptor that is required for GLP-1 secretion in enteroendocrine cells.

  4. data show that the CREB/CRTC2-dependent transcriptional pathway is critical for regulating glucose homeostasis by controlling production of GLP-1 from the L cells at the level of transcription, maturation, and exocytosis.

  5. the results of the present study indicated that GLP1 may be a promising target for the development of novel therapeutic strategies for HGinduced nephropathy, and may function through the activation of SIRT1

  6. this study, we investigated whether glucagon and glucagon-like peptide-1 (GLP-1), hormones produced by alpha cells, contribute to insulin secretion in INS-1 cells, a beta cell line. Co-treatment with glucagon and exendin-4 (Ex-4), a GLP-1 receptor agonist, additively increased glucose-stimulated insulin secretion in INS-1 cells

  7. FXR exerts its function in L cells through interacting with CREB, a crucial transcriptional regulator of cAMP-CREB signaling pathway, to inhibit its transcriptional activity. Targeting FXR to rescue GLP-1 secretion may be a promising strategy for type II diabetes.

  8. results show that glucagon controls gene expression and metabolic zonation in the liver through a counterplay with the Wnt/beta-catenin signaling pathway.

  9. Data (including data from studies using transgenic and knockout mice) suggest that Glp1/Glp1r signaling in insulin-secreting cells plays important role in development of glucose intolerance in obesity; however, Glp1r is not required in insulin-secreting cells for improvement in glucose intolerance after weight loss due to bariatric surgery (here, vertical sleeve gastrectomy).

  10. Chronic stress accelerates DPP4-mediated GLP-1 degradation and alters plasma adiponectin, accelerating vascular senescence and impairing ischemia-induced neovascularization.

  11. Data suggest that metabolism of glutamine and related analogs by Gdh in intestinal L-cells explains why Glp1 secretion, but not that of insulin by pancreatic beta-cells, is activated by these secretagogues. (Gdh = glutamate dehydrogenase; Glp1 = glucagon-like peptide 1)

  12. Glucokinase governs an alpha-cell metabolic pathway that suppresses secretion at or above normoglycemic levels; abnormal suppression of glucagon secretion deregulates hepatic glucose metabolism and, over time, induces a pre-diabetic phenotype.

  13. in colonic crypt cultures, the GLP-1 secretion induced by such Gq + Gs GPR40 agonists is indeed inhibited by blockers of both Gq and Gs and is eliminated by combining these.

  14. Enteric GLP-1 activates NO production by enteric neurons that is impaired in type 2 diabetes. Gut microbiota dysbiosis induces enteric neuropathy. Gut microbiota dysbiosis is responsible for the GLP-1 resistance.

  15. of glucagon-like peptide-1 in vagotomized mice may prevent VLDL overproduction and insulin resistance induced by high-fat diet.

  16. beta-cell function, plasma active GLP-1 levels, the GLP-1R pathway in beta cells and L cell differentiation, were investigated.

  17. CCK/GLP-1 play contributory roles in anorexia induction by trichothecenes T-2 toxin, HT-2 toxin, diacetoxyscirpenol and neosolaniol.

  18. The role of syntaxin 1A in GLP1 release from intestinal cells as a response to external stimuli is reported.

  19. GCG neurons likely stimulate separate populations of downstream cells to produce a change in food intake and glucose homeostasis and that these effects depend on the metabolic state of the animal.

  20. Together, our data indicate effects of AgoPAMs that go beyond glucose lowering previously observed with GPR40 partial agonist treatment with additional potential for weight loss.

Glicentin-related polypeptide (GRPP) Antigen Profile

Protein Summary

The protein encoded by this gene is actually a preproprotein that is cleaved into four distinct mature peptides. One of these, glucagon, is a pancreatic hormone that counteracts the glucose-lowering action of insulin by stimulating glycogenolysis and gluconeogenesis. Glucagon is a ligand for a specific G-protein linked receptor whose signalling pathway controls cell proliferation. Two of the other peptides are secreted from gut endocrine cells and promote nutrient absorption through distinct mechanisms. Finally, the fourth peptide is similar to glicentin, an active enteroglucagon.

Gene names and symbols associated with GRPP

  • glucagon (GCG) antibody
  • glucagon (Gcg) antibody
  • GLP-1 antibody
  • GLP1 antibody
  • GLP2 antibody
  • Glu antibody
  • GRPP antibody
  • PPG antibody

Protein level used designations for GRPP

glicentin-related polypeptide , glucagon-like peptide 1 , glucagon-like peptide 2 , preproglucagon , glucagon-like peptide I

GENE ID SPECIES
2641 Homo sapiens
14526 Mus musculus
Selected quality suppliers for anti-Glicentin-related polypeptide (GRPP) Antibodies
Did you look for something else?